CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts $44.95 -0.54 (-1.19%) (As of 02:52 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 4EstimatedActual EPS (Aug. 5) -$1.49 Missed By -$0.06 Consensus EPS (Aug. 5) -$1.43 Conference Call TranscriptConference Call AudioEarnings Press Release Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCRSP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRSP Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Manward PressThe most important AI company you've never heard ofBecause this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.Get the full story on this secret AI company poised for massive growth CRISPR Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($1.98)($1.19)($1.59)Q2 20244($1.98)($1.14)($1.63)Q3 20244($1.83)($1.18)($1.55)Q4 20244($1.57)($0.10)($0.94)FY 202416($7.36)($3.61)($5.70)Q1 20252($1.57)($1.29)($1.43)Q2 20252($1.56)($1.16)($1.36)Q3 20252($1.42)($1.04)($1.23)Q4 20252($1.33)($0.92)($1.13)FY 20258($5.88)($4.41)($5.15)Q1 20261($1.24)($1.24)($1.24)Q2 20261($0.86)($0.86)($0.86)CRSP Earnings Date and InformationCRISPR Therapeutics last announced its earnings results on August 5th, 2024. The reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by $0.06. The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. Its quarterly revenue was down 99.3% on a year-over-year basis. CRISPR Therapeutics has generated ($2.72) earnings per share over the last year (($2.72) diluted earnings per share). Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.60) to ($4.97) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off prior year's report dates.Read More CRISPR Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/4/2024(Estimated)------- 8/5/2024Q2 2024($1.43)($1.49)($0.06)($1.49)$12.31 million$0.52 million 5/8/2024Q1 2024($1.35)($1.43)($0.08)($1.43)$25.53 million$0.50 million 2/21/2024Q4 2023$0.15$1.10+$0.95$1.10$148.72 million$201.20 million 11/6/2023Q3 2023($2.04)($1.41)+$0.63($1.41)$5.05 million- 8/7/2023Q2 2023($2.13)($0.98)+$1.15($0.98)$1.80 million$70.00 million 5/8/2023Q1 2023($1.64)($0.67)+$0.97($0.67)$24.33 million$100.00 million Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate2/21/2023Q4 2022($2.27)($1.41)+$0.86($1.41)$7.37 million$6.00 million 11/1/2022Q3 2022($2.30)($2.24)+$0.06($2.24)$3.53 million$0.09 million 8/8/2022Q2 2022($2.23)($2.40)($0.17)($2.40)$2.20 million$0.20 million 5/9/2022Q1 2022($1.91)($2.32)($0.41)($2.32)$2.45 million$0.94 million 2/14/2022Q4 2021($1.74)($1.84)($0.10)($1.84)$5.39 million$12.90 million 11/3/2021Q3 2021($1.75)($1.67)+$0.08($1.67)$3.85 million$0.82 million 7/29/2021Q2 2021$3.52$9.44+$5.92$9.44$678.05 million$900.70 million 4/26/2021Q1 2021($1.47)($1.51)($0.04)($1.51)$4.99 million$0.54 million 2/15/2021Q4 2020($1.27)($1.50)($0.23)($1.50)$4.69 million$0.37 million 11/2/2020Q3 2020($1.18)($1.32)($0.14)($1.32)$2.22 million$0.15 million 7/27/2020Q2 2020($0.95)($1.30)($0.35)($1.30)$19.77 million$0.04 million 4/28/2020Q1 2020($1.05)($1.15)($0.10)($1.15)$3.04 million$0.16 million 2/12/2020Q4 2019($0.68)$0.51+$1.19$0.51$39.08 million$77.00 million 10/28/2019Q3($0.9480)$2.40+$3.3480$2.40$6.32 million$211.93 million CRISPR Therapeutics Earnings - Frequently Asked Questions When is CRISPR Therapeutics's earnings date? CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates. Learn more on CRSP's earnings history. Did CRISPR Therapeutics beat their earnings estimates last quarter? In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) missed the analysts' consensus estimate of ($1.43) by $0.06 with a reported earnings per share (EPS) of ($1.49). Learn more on analysts' earnings estimate vs. CRSP's actual earnings. How can I listen to CRISPR Therapeutics's earnings conference call? The conference call for CRISPR Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read CRISPR Therapeutics's conference call transcript? The conference call transcript for CRISPR Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $200 million. How much profit does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$153.61 million. CRSP has generated -$2.72 earnings per share over the last four quarters. What is CRISPR Therapeutics's EPS forecast for next year? CRISPR Therapeutics's earnings are expected to grow from ($5.60) per share to ($4.97) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Allogene Therapeutics Earnings Date Fate Therapeutics Earnings Date Sangamo Therapeutics Earnings Date Adverum Biotechnologies Earnings Date Cellectis Earnings Date Precision BioSciences Earnings Date bluebird bio Earnings Date Vaxcyte Earnings Date Bio-Techne Earnings Date Neurocrine Biosciences Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Nike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season? This page (NASDAQ:CRSP) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredThe most important AI company you've never heard ofBecause this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, G...Manward Press | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.